微生物群
医学
支气管扩张
囊性纤维化
哮喘
免疫学
慢性阻塞性肺病
呼吸道
人病毒体
免疫
呼吸系统
呼吸道感染
肺
疾病
免疫系统
失调
生物信息学
基因组
生物
肠道菌群
病理
内科学
基因
生物化学
作者
Kurtis F. Budden,Shakti D. Shukla,Saima Firdous Rehman,Kate L. Bowerman,Simon Keely,Philip Hugenholtz,Darius Armstrong‐James,Ian M. Adcock,Sanjay H. Chotirmall,Kian Fan Chung,Philip M. Hansbro
标识
DOI:10.1016/s2213-2600(18)30510-1
摘要
The composition of the lung microbiome is increasingly well characterised, with changes in microbial diversity or abundance observed in association with several chronic respiratory diseases such as asthma, cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. However, the precise effects of the microbiome on pulmonary health and the functional mechanisms by which it regulates host immunity are only now beginning to be elucidated. Bacteria, viruses, and fungi from both the upper and lower respiratory tract produce structural ligands and metabolites that interact with the host and alter the development and progression of chronic respiratory diseases. Here, we review recent advances in our understanding of the composition of the lung microbiome, including the virome and mycobiome, the mechanisms by which these microbes interact with host immunity, and their functional effects on the pathogenesis, exacerbations, and comorbidities of chronic respiratory diseases. We also describe the present understanding of how respiratory microbiota can influence the efficacy of common therapies for chronic respiratory disease, and the potential of manipulation of the microbiome as a therapeutic strategy. Finally, we highlight some of the limitations in the field and propose how these could be addressed in future research.
科研通智能强力驱动
Strongly Powered by AbleSci AI